An Open-label Mechanistic Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety of Orally Administered Epeleuton in Patients With Sickle Cell Disease
Latest Information Update: 11 Dec 2024
At a glance
- Drugs Epeleuton (Primary)
- Indications Sickle cell anaemia
- Focus Registrational; Therapeutic Use
- Sponsors Afimmune
Most Recent Events
- 09 Dec 2024 According to an Afimmune media release, results of this trial are expected in 2025
- 21 Oct 2024 Planned End Date changed from 1 Sep 2024 to 1 Sep 2025.
- 21 Oct 2024 Planned primary completion date changed from 1 Aug 2024 to 1 Aug 2025.